rifampin 300 mg/1 CAPSULE
FDA Drug Information
Indications & Usage
INDICATIONS AND USAGE In the treatment of both tuberculosis and the meningococcal carrier state, the small number of resistant cells present within large populations of susceptible cells can rapidly become the predominant type. Bacteriologic cultures should be obtained before the start of therapy to confirm the susceptibility of the organism to rifampin and they should be repeated throughout therapy to monitor the response to treatment. Since resistance can emerge rapidly, susceptibility tests s…
Important Warnings
WARNINGS Hepatotoxicity of hepatocellular, cholestatic, and mixed patterns has been reported in patients treated with rifampin. Severity ranged from asymptomatic elevations in liver enzymes, isolated jaundice/hyperbilirubinemia, symptomatic self-limited hepatitis to fulminant liver failure and death. Severe hepatic dysfunction including fatalities were reported in patients with liver disease and i…
Source: FDA. For professional use only. Not a substitute for prescribing information.
Wholesale and compliance resources
Order NDC 68180-0659-07 at Wholesale
Create a free Premier Pharma account to unlock live wholesale pricing and place orders with same-day fulfillment and full DSCSA T2 documentation (TI + TS).